Use of erythropoietin in two-stage reimplantation total hip arthroplasty

Clinical Orthopaedics and Related Research

Volumn 414, Issue , 2003, Pages 49-54

  Lee, Gwo Chin ^b   Pagnano, Mark W ^a   Jacofsky, David J ^b   Hanssen, Arlen D ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; LIMB REPLANTATION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYMPTOM; TOTAL HIP PROSTHESIS;

EID: 0041817843     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/01.blo.0000084405.53464.5e     Document Type: Conference Paper

References (31)

1. Bertero MT, Caligaris-Cappio F: Anemia of chronic disorders in systemic autoimmune diseases. Haematologica 82:375-381, 1997.
2. Bierbaum BE, Callaghan JJ, Galante JO, et al: An analysis of blood management having total hip or knee arthroplasty. J Bone Joint Surg 81A:2-10, 1999.
3. Blumberg N, Heal JM: Immunomodulation by blood transfusion: An evolving scientific and clinical challenge. Am J Med 101:299-308, 1996.
4. Canadian Orthopedic Perioperative Erythropoetin Study Group: Effectiveness of perioperative recombinant human erythropoetin in elective hip replacement. Lancet 341:1227-1232, 1993.
5. Cazzola M, Mercuriali F, Brugnara C: Use of recombinant human erythropoietin outside the setting of uremia. Blood 89:4248-4267, 1997.
6. Cushner FD, Friedman RJ: Blood loss in total knee arthroplasty. Clin Orthop 269:98-101, 1991.
7. Cushner FD, Locker JR, Hanssen AD, et al: Use of recombinant human erythropoetin in two stage total knee arthroplasty for infection. Clin Orthop 392:116-123, 2001.
8. De Andrade JR, Frei D, Guilfoyle M: Integrated analysis of thrombotic/vascular event occurrence in epoetin alfa-treated patients undergoing major elective orthopedic surgery. Orthopedics 22(Suppl):S113-S118, 1999.
9. De Andradre JR, Jove M, Landon G, et al: Baseline hemoglobin as a predictor of risk of transfusion and response to Epoetin alfa in orthopedic surgery patients. Am J Orthop 25:533-542, 1996.
10. Earnshaw P: Blood conservation in orthopaedic surgery: The role of epoetin alfa. Int Orthop 25:273-278, 2001.
11. Faris PM, Ritter MA, Abels RI: The American Erythropoetin Study Group: The effects of recombinant human erythropoetin on perioperative transfusion requirements in patients having a major orthopaedic operation. J Bone Joint Surg 78A:62-72, 1996.
12. Fitzgerald RH: Infected total hip arthroplasty: Diagnosis and treatment. J Am Acad Orthop Surg 3:249-262, 1995.
13. Garvin KL, Hanssen AD: Infection after total hip arthroplasty. J Bone Joint Surg 77A:1576-1588, 1995.
14. Goodnough LT, Price TH, Friedman KD, Johnston M, et al: A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: Dose, response, toxicity, and efficacy. Transfusions 34:66-71, 1994.
15. Jefferies LC, Sachais BS, Young DS: Blood transfusion costs by diagnosis-related groups in 60 university hospitals in 1995. Transfusion 41:522-529, 2001.
16. Johnson CS, Cook CA, Furmanski P: In vivo suppression of ertyhropoesis by tumor necrosis factor-alpha (TNF-alpha): Reversal with exogenous erythropoetin (EPO). Exp Hematol 18:109-113, 1990.
17. Keating EM, Ranawat CS, Cats-Baril W: Assessment of postoperative vigor in patient's undergoing elective total joint arthroplasty: A concise patient and caregiver based instrument. Orthopedics 22(Suppl 1):S119-S128, 1999.
18. Kim DM, Brecher ME, Estes TJ, Morrey BF: Relationship of hemoglobin level and duration of hospitalization after total hip arthroplasty: Implications for the transfusion target. Mayo Clin Proc 68:37-41, 1993.
19. Marx RG, Wotherspoon S, Stephens D, Davey JR: Patient factors affecting autologous and allogeneic blood transfusion rates in total hip arthroplasty. Am J Orthop 30:867-871, 2001.
20. Masri BA, Salvati EA: Sepsis: Two-Stage Exchange. In Callaghan JJ, Rosenberg AG, Rubash HE (eds). The Adult Hip. Philadelphia, Lippincott-Raven Publishers 1317-1329, 1998.
21. Means Jr RT: Erythropoetin in the treatment of anemia of chronic infectious, inflammatory, and malignant diseases. Curr Opin Hematol 2:210-213, 1995.
22. Means Jr RT, Krantz SB: Inhibition of human erythroid colony-forming units by gamma interferon can be corrected by recombinant human erythropoetin. Blood 78:2564-2567, 1991.
23. Salvati EA, Chekofsky KM, Brause BD: Reimplantation in infection: A 12 year experience. Clin Orthop 170:62-75, 1982.
24. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ: The risk of transfusion transmitted viral infections. N Engl J Med 334:1685-1690, 1996.
25. Soignet S: Management of cancer related anemia: Epoetin alfa and quality of life. Semin Hematol 37(4 Suppl 6):9-13, 2000.
26. Stowell CP, Chandler H, Jove M, Guilfoyle M, Wacholtz MC: An open-label, randomized study to compare the safety and efficacy of perioperative epoetin alfa with preoperative autologous blood donation in total joint arthroplasty. Orthopedics 22(Suppl 1):S105-S112, 1999.
27. Tawes Jr RL: Intraoperative autotransfusion: Advantages, disadvantages, and contraindications. Semin Vasc Surg 7:95-97, 1994.
28. Toy PT, Kaplan EB, McVay PA, Lee SJ, et al: Blood loss and replacement in total hip arthroplasty: A multicenter study: The preoperative autologous blood donation group. Transfusion 32:663-667, 1992.
29. Vamvakas EC, Blajchman MA: Deleterious clinical effects of transfusion associated immunomodulation: Factor or fiction? Blood 97:1180-1195, 2001.
30. Vamvakas EC, Moore SB, Cabanela M: Blood transfusions and septic complications after hip replacement surgery. Transfusion 35:150-156, 1995.
31. Walker RW, Rosson JR, Bland JM: Blood loss during primary total hip arthroplasty: Use of preoperative measurements to predict the need for transfusion. Ann R Coll Surg Engl 79:438-440, 1997.